Galena Biopharma, Inc. dismissed BDO Seidman, LLP (BDO) as independent registered public accounting firm. The Audit Committee of Board of Directors approved the dismissal of BDO. During the fiscal years ended December 31, 2012 and 2011 and through May 13, 2013, there were: no disagreements with BDO on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of BDO, would have caused it to make reference thereto in connection with its reports on the financial statements for such years; and no reportable events within the meaning set in Item 304(a)(1)(v) of Regulation S-K. On May 16, 2013, the Audit Committee of Board of Directors engaged Moss Adams LLP (Moss Adams) as new independent registered public accounting firm.

Galena Biopharma, Inc. reported unaudited consolidated earnings results for first quarter ended March 31, 2013. For the period, the company reported operating loss was $6,611,000 against $4,410,000 in the same period last year. Pretax loss - continuing operations was $12,055,000 against $23,540,000 in the same period last year. Net loss from continuing operations was $9,293,000 or $0.11 per basic and diluted share against $23,540,000 or $0.49 per basic and diluted share last year. Net loss was $9,293,000 or $0.11 per basic and diluted share against loss of $24,761,000 or $0.52 per basic and diluted share last year.

Galena Biopharma announced the addition of William L. Ashton to the company's Board of Directors. Most recently, at Amgen, Inc., Mr. Ashton served as Vice President of corporate and government affairs and Vice President of sales, and was directly responsible for product launches, as well as key government agencies including Centers for Medicare and Medicaid Services, Office of Inspector General, General Accounting Office, Office of Management and Budget, and MedPAC. After retiring from Amgen, Mr. Ashton joined the University of the Sciences in Philadelphia where he currently serves as Associate Provost and Senior Vice President of Strategic Business Development, Founding Dean, Mayes College of Healthcare Business and Policy, and Assistant Professor of Pharmaceutical Business. Mr. Ashton is on the boards of the National Osteoporosis Foundation, Friends of the National Library of Medicine (NIH), and a commissioner for the Medical Representatives National Certificate Commission. He currently serves on the board of Sucampo Pharmaceuticals. He received his Bachelor of Science from California University of Pennsylvania and his Master of Science from the University of Pittsburgh.